Clinical trial
A Phase I, Double Blind, Placebo-controlled, Randomized 4-way Alternating Cross-over Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Single Ascending Doses of ASP3652 in Healthy Young Caucasian Male and Female Subjects
NCT01815684 is registered in ClinicalTrials.gov with Astellas Pharma Europe B.V. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Double Blind, Placebo-controlled, Randomized 4-way Alternating Cross-over Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Single Ascending Doses of ASP3652 in Healthy Young Caucasian Male and Female Subjects
- Lead sponsor
- Astellas Pharma Europe B.V.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 31, 2012
- Completion date
- December 31, 2012
- Enrollment
- 26 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
healthy subjects, pharmacodynamics, pharmacokinetics, safety